Advertisement

Adaptive Randomization of Neratinib in Early Breast Cancer

Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer.

 New England Journal of Medicine